Ellis D A, Neville E, Hall R J
Thorax. 1983 Dec;38(12):903-7. doi: 10.1136/thx.38.12.903.
Major pulmonary embolism occurring insidiously over several weeks (subacute massive pulmonary embolism) has a high mortality and may not respond well to standard anticoagulant or thrombolytic treatment. A priming dose of plasminogen was used to enhance thrombolysis produced by a streptokinase infusion in five consecutive patients with subacute massive pulmonary embolism. In each patient a dramatic clinical improvement occurred with a substantial increase in pulmonary blood flow. All five patients survived to leave hospital. Malignant disease was the underlying cause of embolism in three patients, two of whom died of their malignant disease in the six months after treatment of their pulmonary embolism. The third patient with malignant disease had a choriocarcinoma; at least some of the pulmonary obstruction may have been tumour tissue but this obstruction was dramatically cleared by the treatment. The use of a combination of plasminogen with streptokinase should be considered in severely ill patients with subacute massive pulmonary embolism, particularly if other treatment, including streptokinase alone, has failed.
数周内隐匿发生的大面积肺栓塞(亚急性大面积肺栓塞)死亡率很高,对标准抗凝或溶栓治疗可能反应不佳。对连续5例亚急性大面积肺栓塞患者使用纤溶酶原首剂负荷量以增强链激酶输注所产生的溶栓作用。每例患者临床症状均显著改善,肺血流量大幅增加。所有5例患者均存活出院。3例患者肺栓塞的潜在病因是恶性疾病,其中2例在肺栓塞治疗后的6个月内死于恶性疾病。第3例患有恶性疾病的患者为绒毛膜癌;至少部分肺阻塞可能是肿瘤组织,但该阻塞经治疗后显著消除。对于患有亚急性大面积肺栓塞的重症患者,尤其在包括单用链激酶在内的其他治疗失败时,应考虑使用纤溶酶原与链激酶联合治疗。